Multiple myeloma has historically been considered a chronic disease, even as newer treatments have greatly improved rates of survival for the disease.
Traditionally thought of as a disease that cannot be cured, researchers of a new paper in Advances in Oncology are posing the possibility of a cure in multiple myeloma (MM).
MM has historically been considered a chronic disease, even as newer treatments have greatly improved rates of survival for the disease. Despite improved survival, many patients who are able to achieve complete responses (CRs) to treatment often eventually experience disease progression.
“Multiple myeloma is a particularly challenging malignancy in which to define cure because of its often indolent nature that leads to an alternating pattern of disease response and progression,” explained the researchers. “It is for this reason that the International Myeloma Working Group (IMWG) response criteria specifically use ‘response’ and do not use the word ‘remission’ as is used in other malignancies.’
However, according to the group, there is a possibility for MM to be considered a curable disease, which they outlined as being defined by: no evidence of disease, no longer on treatment, limited or no comorbidities, and mortality that is similar to age-match controls.
The group highlighted the utility of minimal residual disease (MRD), which has gained credibility as a prognostic tool, for determining absence of disease and predicting long-term outcomes. A growing amount of research has shown MRD to be a more reliable prognostic indicator than more traditional markers, such as CR or sustained CR.
Specifically, the researchers underscored the use of sustain MRD negativity, defined as 2 consecutive negative MRD results done at least 1 year apart. The group cited several studies, including the phase 2 FORTE study of patients with MM, in which sustained MRD-negativity was associated with superior progression-free survival.
“If sustained MRD-negativity becomes one of the key checkpoints to a functional cure, then the eradication of MRD becomes essential for patients with MM who have not experienced clinical progression,” wrote the group. “This, of course, has important implications to patients, clinicians, and whomever else is bearing the cost of interventions to eradicate MRD. A combined risk and MRD-adapted strategy may prove to be an intriguing treatment approach to intensity treatment for those who might most benefit, using immunotherapeutic modalities such as monoclonal antibodies, bispecific T-cell redirectors, and/or chimeric antigen receptor T-cell therapy.”
Honing in on indicators for which patients may considered cured, the researchers highlighted patients who are considered exceptional responders—those without disease progression or death at least 8 years after starting treatment—the researchers argue that newer treatments may results in as many as 30% to 40% of patients being exceptional responders.
For example, in the phase 3 GIMEMA-MMY-3006 study of bortezomib, thalidomide, a d dexamethasone (VTd) versus Td followed by tandem ASCT, 2 cycles of consolidation, and maintenance therapy with dexamethasone, VTd yielded a 10-year PFS rate of 34%.
Reference
Derman B, Jakubowiak A. Moving toward a cure in multiple myeloma: Eradication of measurable residual disease. Adv in Oncol. 2022;2(1);159-169. doi:10.1016/j.yao.2022.02.012
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Disease-Modifying Antirheumatic Drugs Linked to Decreased Risk for Autoimmune Thyroid Disease
November 28th 2023A nationwide cohort study linked biologic disease-modifying antirheumatic drugs with decreased risks for the onset of autoimmune thyroid disease in patients with rheumatoid arthritis.
Read More
Reaching Rural America: Value-Based Care Solutions for Systemic Health and Social Inequalities
March 7th 2023On this episode of Managed Care Cast, we speak with Jennifer Schneider, MD, co-founder and chief executive officer of Homeward, a value-based care provider aiming to improve access to high-quality care in rural communities through tech-enabled clinical services, partnerships with local physicians and health plans, and community-level demographic data.
Listen
Gene Therapy Success in UK Likely Depends on Overcoming Education, Psychological Support Challenges
November 27th 2023Education, psychological support, and implementation guidance are the top unmet needs identified by investigators from the United Kingdom concerning gene therapy use for hemophilia.
Read More